In addition to chemotherapeutic drugs and EGFR-TKI inhibitors, the combination of STAT3 inhibitors and other small molecular inhibitors has also achieved promising therapeutic effects on lung cancer. The gene discussed is STAT3; the disease is lung carcinoma.